Why Is Identifai Genetics (ASX:ID1) Trading Lower Today?

Sonal Goyal

26 October 2026 04:59 PM AEDT

Why Is Identifai Genetics (ASX:ID1) Trading Lower Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Identifai Genetics (ASX:ID1) shares traded at $0.405, down 15.63%, during the 26 October 2026 session.
The share swap with Identifai Israel completed on 16 July 2026.
The company was incorporated on 18 February 2026 and has a limited operating history.

Identifai Genetics Ltd (ASX:ID1) shares traded at $0.405, down 15.63%, during the Trading session on 26 October 2026, while the S&P/ASX 200 index (XJO) stood at 8,805.30, up 0.11% or 10.10 points, at 2:06 pm. Separately, the company's latest announcement on file is dated 16 July 2026 and covers its interim report for the period 1 January 2026 to 16 July 2026.

Identifai Genetics is developing AI-based prenatal genetic screening through its Israeli subsidiary, and the report describes its corporate structure ahead of ASX admission. The release is dated earlier than the session, so the share price movement and the announcement are reported as separate items.

Interim report and structure (16 July 2026)

The report covers 1 January to 16 July 2026. Identifai Genetics Pty Limited was incorporated on 18 February 2026, converted to a public company and renamed Identifai Genetics Limited on 19 June 2026, and is the entity seeking admission to the ASX official list. Its activities are conducted through Identifai Israel and Identifai Genetics Inc., a Delaware company, with operations currently run from Israel.

Swap agreement

On 11 June 2026 the company signed a Swap Agreement under which shareholders of Identifai Israel became shareholders of the company and the company became sole Shareholder of Identifai Israel. The swap completed on 16 July 2026. The report lists several directors appointed between February and July 2026, one of whom resigned on 28 July 2026, and a company secretary appointed on 18 February 2026.

About Identifai Genetics

Identifai Israel was founded in 2021 to apply genome-wide sequencing and artificial intelligence to detect fetal genetic disorders from maternal blood samples taken in the first trimester of pregnancy. Identifai Genetics Limited (ASX:ID1) is its listed parent.

Related sector context

Non-invasive prenatal testing uses maternal blood samples to screen for genetic conditions, and diagnostics companies seek regulatory approvals and clinical validation in each market. The report notes the Business is at an early stage.

The XJO was up 0.11% at 2:06 pm on the day.

Risks to weigh in

The company has a limited operating history, was incorporated in 2026 and is newly structured. Board changes occurred within months, and a commercial diagnostics business requires regulatory approvals and funding.

Catalysts on watch

Items to follow include post-listing reporting, commercial and regulatory milestones in prenatal screening and the first full financial statements.

Wrapping up

Identifai Genetics (ASX:ID1) traded 15.63% lower during the 26 October 2026 session, while its latest release, dated 16 July 2026, covered the company's formation and the Identifai Israel share swap.

FAQs

Q: How did Identifai Genetics (ASX:ID1) shares trade on 26 October 2026?

A: Shares traded at $0.405, down 15.63%, during the trading session, while the S&P/ASX 200 was up 0.11% at 2:06 pm.

Q: What does Identifai Genetics (ASX:ID1) do?

A: Its Israeli subsidiary applies sequencing and AI to detect fetal genetic disorders from maternal blood in the first trimester.

Q: When did the swap complete?

A: 16 July 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.